1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Remibrutinib REMIXes The Itch Record

 
• By Elizabeth Cairns

Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.  

Itching

Novartis AG and Roche Holding AG’s Xolair (omalizumab) has held a monopoly in chronic spontaneous urticaria for some years. Now, though, another agent might end Xolair’s solo reign: Novartis’s own remibrutinib.

Key Takeaways
  • Novartis’s remibrutinib looks set to join Xolair as an approved therapy for chronic spontaneous urticaria

New data from the twin pivotal trials of remibrutinib, REMIX-1 and -2, suggest that the BTK inhibitor works well whether...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from R&D

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.